<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LITHIUM CARBONATE- lithium carbonate tablet, extended release </strong><br>Carilion Materials Management<br></p></div>
<h1>LITHIUM CARBONATE Extended Release Tablets USP, 450 mg</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_401d21fd-451d-4768-9a4c-7b97b7a7f588"></a><a name="section-1"></a><p></p>
<h1>Rx only</h1>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_32ed4a7a-2c01-40df-95f6-46bbd6767159"></a><a name="section-2"></a><p></p>
<h1>WARNING</h1>
<div class="Warning">
<a name="id_d0490c2f-19d6-4618-bda1-017e75e2bf5c"></a><a name="section-2.1"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium toxicity</span> is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy (see ).
                                    <a href="#i4i_dosage_admin_id_2e1b737e-a948-439a-b156-9bd6f490b0a7">DOSAGE AND ADMINISTRATION</a></p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_0aa80ff5-9b9e-42d6-adfd-3cce62e91bef"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Lithium Carbonate Extended Release Tablets USP contain lithium carbonate, a white, light alkaline powder with molecular formula Li CO and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94 and an emission line at 671 nm on the flame photometer.
                            <span class="Sub">2</span><span class="Sub">3</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d8a0bebd-7285-4128-a5dd-795338f5658c"></a><a name="section-3.1"></a><p></p>
<h2>Lithium Carbonate Extended Release Tablets USP</h2>
<p class="First">Each round, speckled off-white to yellow, biconvex tablet debossed with "54 346" on one side and scored on the other side, contains lithium carbonate, 450 mg. Inactive ingredients consist of ferric oxide, magnesium stearate, povidone, sodium alginate, and sodium starch glycolate.</p>
<p>Lithium Carbonate Extended Release Tablets USP, 450 mg are designed to release a portion of the dose initially and the remainder gradually; the release pattern of the controlled release tablets reduces the variability in lithium blood levels seen with the immediate release dosage forms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_c77b2d16-b1a1-4851-9459-4ee518d47147"></a><a name="section-4"></a><p></p>
<h1>ACTIONS</h1>
<p class="First">Preclinical studies have shown that lithium alters sodium transport in nerve and muscle cells and effects a shift toward intraneuronal metabolism of catecholamines, but the specific biochemical mechanism of lithium action in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> is unknown.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_5ea2b2d6-44e5-41b5-a935-49872a09bcd3"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">Lithium Carbonate Extended Release Tablets USP are indicated in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span>. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-depressive patients with a history of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>.</p>
<p>Typical symptoms of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> include pressure of speech, motor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span> and possibly <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>. When given to a patient experiencing a <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span>, Lithium Carbonate Extended Release Tablets USP may produce a normalization of symptomatology within 1 to 3 weeks.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_dbc01f71-f701-4193-bec0-56591e0cf1dc"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_516d24ea-990a-4814-a5dd-e86c64a104c4"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium Toxicity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium toxicity</span> is closely related to serum lithium levels, and can occur at doses close to therapeutic levels (see ).
                                    <a href="#i4i_dosage_admin_id_2e1b737e-a948-439a-b156-9bd6f490b0a7">DOSAGE AND ADMINISTRATION</a></p>
<p>Outpatients and their families should be warned that the patient must discontinue lithium carbonate therapy and contact his physician if such clinical signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, mild <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> occur.</p>
<p>Lithium carbonate may impair mental and/or physical abilities. Caution patients about activities requiring alertness (e.g., operating vehicles or machinery).</p>
<p>Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation or <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">sodium depletion</span>, since the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> is very high in such patients. If the psychiatric indication is life-threatening, and if such a patient fails to respond to other measures, lithium treatment may be undertaken with extreme caution, including daily serum lithium determinations and adjustment to the usually low doses ordinarily tolerated by these individuals. In such instances, hospitalization is a necessity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb38810d-b6cc-4f14-9671-44e83b1fe876"></a><a name="section-6.2"></a><p></p>
<h2>Unmasking of <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span></h2>
<p class="First">There have been postmarketing reports of a possible association between treatment with lithium and the unmasking of <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span>. <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span> is a disorder characterized by abnormal electrocardiographic (ECG) findings and a risk of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. Lithium should generally be avoided in patients with <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span> or those suspected of having <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span>. Consultation with a cardiologist is recommended if: (1) treatment with lithium is under consideration for patients suspected of having <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span> or patients who have risk factors for <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span>, e.g., unexplained <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, a family history of <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span>, or a family history of sudden unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> before the age of 45 years, (2) patients who develop unexplained <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> after starting lithium therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8942d2eb-b57c-4f9b-b4aa-553d5d75493d"></a><a name="section-6.3"></a><p></p>
<h2>Renal Effects</h2>
<p class="First">Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>, with <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>. Such patients should be carefully managed to avoid <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> with resulting lithium retention and toxicity. This condition is usually reversible when lithium is discontinued.</p>
<p>Morphologic changes with glomerular and interstitial <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and nephron <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> have been reported in patients on chronic lithium therapy. Morphologic changes have also been seen in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-depressive patients never exposed to lithium. The relationship between renal functional and morphologic changes and their association with lithium therapy have not been established.</p>
<p>When kidney function is assessed, for baseline data prior to starting lithium therapy or thereafter, routine urinalysis and other tests may be used to evaluate tubular function (e.g., urine specific gravity or <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> following a period of water deprivation, or 24-hour urine volume) and glomerular function (e.g., serum creatinine or creatinine clearance). During lithium therapy, progressive or sudden changes in renal function, even within the normal range, indicate the need for reevaluation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9c2da3e8-a358-490c-be71-f170ea96d18f"></a><a name="section-6.4"></a><p></p>
<h2>Encephalopathic Syndrome</h2>
<p class="First">An encephalopathic syndrome (characterized by <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, elevated serum enzymes, BUN and FBS) has occurred in a few patients treated with lithium plus a neuroleptic. In some instances, the syndrome was followed by irreversible <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span>. Because of a possible causal relationship between these events and the concomitant administration of lithium and neuroleptics, patients receiving such combined therapy should be monitored closely for early evidence of neurologic toxicity and treatment discontinued promptly if such signs appear. This encephalopathic syndrome may be similar to or the same as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> (NMS).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e8b3ed9d-b276-4bcc-b027-dce7500123e2"></a><a name="section-6.5"></a><p></p>
<h2>Concomitant Use With Neuromuscular Blocking Agents</h2>
<p class="First">Lithium may prolong the effects of neuromuscular blocking agents. Therefore, neuromuscular blocking agents should be given with caution to patients receiving lithium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5294a52b-9865-45d6-88f5-b80c22af434e"></a><a name="section-6.6"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">Adverse effects on implantation in rats, embryo viability in mice and metabolism of rat testes and human spermatozoa have been attributed to lithium, as have <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in submammalian species and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> in mice.
                                    <span class="Italics">in vitro</span></p>
<p>In humans, lithium carbonate may cause fetal harm when administered to a pregnant woman. Data from lithium birth registries suggest an increase in cardiac and other anomalies, especially Ebstein's anomaly. If this drug is used in women of childbearing potential, or during pregnancy, or if a patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_38ae3617-1223-4756-9b7b-810a08d16599"></a><a name="section-6.7"></a><p></p>
<h2>Usage in Nursing Mothers</h2>
<p class="First">Lithium is excreted in human milk. Nursing should not be undertaken during lithium therapy except in rare and unusual circumstances where, in the view of the physician, the potential benefits to the mother outweigh possible hazards to the child.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b22bc37d-780c-409b-8274-7f8bbe664c58"></a><a name="section-6.8"></a><p></p>
<h2>Usage in Pediatric Patients</h2>
<p class="First">Since information regarding the safety and effectiveness of lithium carbonate in children under 12 years of age is not available, its use in such patients is not recommended.</p>
<p>There has been a report of a transient syndrome of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> and <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span> occurring in a 15 kg child who ingested 300 mg of lithium carbonate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c500ee2-dc8a-4ea7-b210-9f969a7f03e2"></a><a name="section-6.9"></a><p></p>
<h2>Usage in the Elderly</h2>
<p class="First">Elderly patients often require lower lithium dosages to achieve therapeutic serum levels. They may also exhibit adverse reactions at serum levels ordinarily tolerated by younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_1642dbd6-4233-4642-8f21-ab84b7ae4b77"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3170d29e-4f5e-4107-bf95-d024a55b4ea0"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The ability to tolerate lithium is greater during the acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> phase and decreases when <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms subside (see ).
                                    <a href="#i4i_dosage_admin_id_2e1b737e-a948-439a-b156-9bd6f490b0a7">DOSAGE AND ADMINISTRATION</a></p>
<p>The distribution space of lithium approximates that of total body water. Lithium is primarily excreted in urine with insignificant excretion in feces. Renal excretion of lithium is proportional to its plasma concentration. The half-life of elimination of lithium is approximately 24 hours. Lithium decreases sodium reabsorption by the renal tubules which could lead to <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">sodium depletion</span>. Therefore, it is essential for the patient to maintain a normal diet, including salt, and an adequate fluid intake (2500 to 3000 mL) at least during the initial stabilization period. Decreased tolerance to lithium has been reported to ensue from protracted <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and, if such occur, supplemental fluid and salt should be administered under careful medical supervision and lithium intake reduced or suspended until the condition is resolved.</p>
<p>In addition to <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, concomitant <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with elevated temperatures may also necessitate a temporary reduction or cessation of medication.</p>
<p>Previously existing underlying <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorders</span> do not necessarily constitute a contraindication to lithium treatment; where <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> exists, careful monitoring of thyroid function during lithium stabilization and maintenance allows for correction of changing thyroid parameters, if any; where <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> occurs during lithium stabilization and maintenance, supplemental thyroid treatment may be used.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_04c1ca61-5201-46f9-b704-c2f674219a58"></a><a name="section-7.2"></a><p></p>
<h2>Information for the Patient</h2>
<p class="First">A condition known as <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span> may pre-exist and be unmasked by lithium therapy. <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span> is a <span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">heart disorder</span> characterized by abnormal electrocardiographic (ECG) findings and risk of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. Patients should be advised to seek immediate emergency assistance if they experience <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, abnormal heart beats, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_4fc9cdd8-7141-43fa-b927-bd602a1271e9"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Caution should be used when lithium and diuretics are used concomitantly because diuretic-induced sodium loss may reduce the renal clearance of lithium and increase serum lithium levels with risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Patients receiving such combined therapy should have serum lithium levels monitored and the lithium dosage adjusted if necessary.</p>
<p>Lithium levels should be closely monitored when patients initiate or discontinue NSAID use. In some cases, <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> has resulted from interactions between an NSAID and lithium. Indomethacin and piroxicam have been reported to increase significantly steady-state plasma lithium concentrations. There is also evidence that other nonsteroidal anti-inflammatory agents, including the selective cyclooxygenase-2 (COX-2) inhibitors, have the same effect. In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg b.i.d. with celecoxib 200 mg b.i.d. as compared to subjects receiving lithium alone.</p>
<p>Concurrent use of metronidazole with lithium may provoke <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> due to reduced renal clearance. Patients receiving such combined therapy should be monitored closely.</p>
<p>There is evidence that angiotensin-converting enzyme inhibitors, such as enalapril and captopril, and angiotension II receptor antagonists, such as losartan, may substantially increase steady-state plasma lithium levels, sometimes resulting in <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. When such combinations are used, lithium dosage may need to be decreased, and plasma lithium levels should be measured more often.</p>
<p>Concurrent use of calcium channel blocking agents with lithium may increase the risk of <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> in the form of <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and/or <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. Caution is recommended.</p>
<p>The concomitant administration of lithium with selective serotonin reuptake inhibitors should be undertaken with caution as this combination has been reported to result in symptoms such as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>.</p>
<p>The following drugs can lower serum lithium concentrations by increasing urinary lithium excretion: acetazolamide, urea, xanthine preparations and alkalinizing agents such as sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</p>
<p>The following have also been shown to interact with lithium: methyldopa, phenytoin and carbamazepine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_6e988eab-17b0-4fc3-9ec3-35587cced7ba"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The occurrence and severity of adverse reactions are generally directly related to serum lithium concentrations as well as to individual patient sensitivity to lithium, and generally occur more frequently and with greater severity at higher concentrations.</p>
<p>Adverse reactions may be encountered at serum lithium levels below 1.5 mEq/L. Mild to moderate adverse reactions may occur at levels from 1.5 to 2.5 mEq/L, and moderate to severe reactions may be seen at levels of 2 mEq/L and above.</p>
<p>Fine hand <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and mild <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> may occur during initial therapy for the acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> phase, and may persist throughout treatment. Transient and mild <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">general discomfort</span> may also appear during the first few days of lithium administration.</p>
<p>These side effects usually subside with continued treatment or a temporary reduction or cessation of dosage. If persistent, cessation of lithium therapy may be required.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> and <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">lack of coordination</span> may be early signs of lithium <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, and can occur at lithium levels below 2 mEq/L. At higher levels, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">giddiness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and a large output of dilute urine may be seen. Serum lithium levels above 3 mEq/L may produce a complex clinical picture, involving multiple organs and organ systems. Serum lithium levels should not be permitted to exceed 2 mEq/L during the acute treatment phase.</p>
<p>The following reactions have been reported and appear to be related to serum lithium levels, including levels within the therapeutic range:</p>
<p><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, muscle hyperirritability (<span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculations</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonic movements</span> of whole limbs), <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonicity</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, choreo-athetotic movements, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> deep tendon reflex, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> including <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">blackout spells</span>, epileptiform <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, downbeat <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">incontinence of urine</span> or feces, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4160898" conceptname="Motor retardation">psychomotor retardation</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, tongue movements, <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, poor memory, slowed intellectual functioning, startled response, worsening of <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">organic brain syndromes</span>, <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> (rarely).
                            <span class="Bold">Neuromuscular/Central Nervous System:</span></p>
<p><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, peripheral <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, sinus node dysfunction with severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (which may result in <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>), unmasking of <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span> (See and ).
                            <span class="Bold">Cardiovascular:</span><span class="Bold">WARNINGS: Unmasking of <span class="product-label-link" type="condition" conceptid="4303408" conceptname="Brugada syndrome">Brugada Syndrome</span></span><span class="Bold"><a href="#i4i_info_patients_id_04c1ca61-5201-46f9-b704-c2f674219a58">PRECAUTIONS: Information for the Patients</a></span></p>
<p><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="28461" conceptname="Hypertrophy of salivary gland">salivary gland swelling</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, excessive <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>.
                            <span class="Bold">Gastrointestinal:</span></p>
<p><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, decreased creatinine clearance, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and symptoms of <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span> including <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>.
                            <span class="Bold">Genitourinary:</span></p>
<p>drying and thinning of hair, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, anesthesia of skin, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, chronic <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, xerosis cutis, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or its exacerbation, <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">generalized pruritus</span> with or without <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, cutaneous <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.
                            <span class="Bold">Dermatologic:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>/<span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>.
                            <span class="Bold">Autonomic:</span></p>
<p><span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">euthyroid goiter</span> and/or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> (including <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span>) accompanied by lower T and T . I uptake may be elevated. (See .) Paradoxically, rare cases of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> have been reported.
                            <span class="Bold">Thyroid Abnormalities:</span><span class="Sub">3</span><span class="Sub">4</span><span class="Sup">131</span><a href="#i4i_precautions_id_1642dbd6-4233-4642-8f21-ab84b7ae4b77">PRECAUTIONS</a></p>
<p>diffuse slowing, widening of the frequency spectrum, potentiation and disorganization of background rhythm.
                            <span class="Bold">EEG Changes:</span></p>
<p>reversible flattening, isoelectricity or inversion of T-waves.
                            <span class="Bold">EKG Changes:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, transient scotomata, <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">exophthalmos</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, transient <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>, excessive <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, edematous <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of ankles or wrists, metallic taste, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>/taste distortion, salty taste, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">swollen lips</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">tightness in chest</span>, swollen and/or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">painful joints</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">polyarthralgia</span>, <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">dental caries</span>.
                            <span class="Bold">Miscellaneous:</span></p>
<p>Some reports of <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>, <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> and <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> which persist after lithium discontinuation have been received.</p>
<p>A few reports have been received of the development of painful discoloration of fingers and toes and <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span> of the extremities within one day of the starting of treatment with lithium. The mechanism through which these symptoms (resembling Raynaud's syndrome) developed is not known. Recovery followed discontinuance.</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> (<span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> and <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>) have been reported with lithium use. If undetected, this condition may result in enlargement of the blind spot, constriction of visual fields and eventual <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> due to <span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">optic atrophy</span>. Lithium should be discontinued, if clinically possible, if this syndrome occurs.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_2e1b737e-a948-439a-b156-9bd6f490b0a7"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Doses of extended-release tablets are usually given b.i.d. (approximately 12-hour intervals). When initiating therapy with immediate-release or extended-release lithium, dosage must be individualized according to serum levels and clinical response.</p>
<p>When switching a patient from immediate-release capsules to the Lithium Carbonate Extended Release Tablets, give the same total daily dose when possible. Most patients on maintenance therapy are stabilized on 900 mg daily, e.g., Lithium Carbonate Extended Release Tablets, 450 mg b.i.d. When the previous dosage of immediate-release lithium is not a multiple of 450 mg, e.g., 1500 mg, initiate lithium extended-release tablet at the multiple of 450 mg nearest to, but , the original daily dose, i.e., 1350 mg. When the two doses are unequal, give the larger dose in the evening. In the above example, with a total daily dose of 1350 mg, generally 450 mg of Lithium Carbonate Extended Release Tablets should be given in the morning and 900 mg of Lithium Carbonate Extended Release Tablets in the evening. If desired, the total daily dose of 1350 mg can be given in three equal 450 mg doses of Lithium Carbonate Extended Release Tablets. These patients should be monitored at 1- to 2-week intervals, and dosage adjusted if necessary, until stable and satisfactory serum levels and clinical state are achieved.
                            <span class="Italics">below</span></p>
<p>When patients require closer titration than that available with doses of lithium carbonate extended-release tablets in increments of 450 mg, immediate-release capsules should be used.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bcbe5667-5281-4fcd-9452-4e302ff43d90"></a><a name="section-9.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Acute Mania</span></h2>
<p class="First">Optimal patient response to lithium can usually be established and maintained with 1800 mg per day in divided doses. Such doses will normally produce the desired serum lithium level ranging between 1 and 1.5 mEq/L.</p>
<p>Dosage must be individualized according to serum levels and clinical response. Regular monitoring of the patient's clinical state and serum lithium levels is necessary. Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3b1552b2-20b7-43db-aea7-efd178759e23"></a><a name="section-9.2"></a><p></p>
<h2>Long-Term Control</h2>
<p class="First">The desirable serum lithium levels are 0.6 to 1.2 mEq/L. Dosage will vary from one individual to another, but usually 900 mg to 1200 mg per day in divided doses will maintain this level. Serum lithium levels in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months.</p>
<p>Patients unusually sensitive to lithium may exhibit toxic signs at serum levels below 1 mEq/L.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e5831098-6b14-4405-bf7a-1a05f3e5027d"></a><a name="section-9.3"></a><p></p>
<h2>N.B.</h2>
<p class="First">Blood samples for serum lithium determinations should be drawn immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 8 to 12 hours after the previous dose). Total reliance must not be placed on serum levels alone. Accurate patient evaluation requires both clinical and laboratory analysis.</p>
<p>Elderly patients often respond to reduced dosage, and may exhibit signs of toxicity at serum levels ordinarily tolerated by younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_b244d6ba-e75d-4696-819e-3a5dcb811f3f"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The toxic levels for lithium are close to the therapeutic levels. It is therefore important that patients and their families be cautioned to watch for early toxic symptoms and to discontinue the drug and inform the physician should they occur. Toxic symptoms are listed in detail under .
                            <a href="#i4i_adverse_effects_id_6e988eab-17b0-4fc3-9ec3-35587cced7ba">ADVERSE REACTIONS</a></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ed989a5b-6477-4101-804c-a59f086cef91"></a><a name="section-10.1"></a><p></p>
<h2>Treatment</h2>
<p class="First"><span class="Bold">No specific antidote for <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium poisoning</span> is known. Early symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> can usually be treated by reduction or cessation of dosage of the drug and resumption of the treatment at a lower dose after 24 to 48 hours. In severe cases of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium poisoning</span>, the first and foremost goal of treatment consists of elimination of this ion from the patient. Treatment is essentially the same as that used in barbiturate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>: 1) gastric lavage, 2) correction of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, and 3) regulation of kidney function. Urea, mannitol and aminophylline all produce significant increases in lithium excretion. Hemodialysis is an effective and rapid means of removing the ion from the severely toxic patient. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> prophylaxis, regular chest X-rays and preservation of adequate respiration are essential.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_14837eb0-171a-437d-aac3-f03a336aac71"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NDC:68151-0245-2 in a PACKAGE of 1 TABLET, EXTENDED RELEASES</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aab470cb-9d50-4151-b1c7-be008b8a6dda"></a><a name="section-11.1"></a><p></p>
<h2>Storage Conditions</h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</p>
<p><span class="Bold">10002294/04</span><span class="Bold">Revised December 2011</span></p>
<p>© RLI, 2011</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a1baef0a-f748-453a-84ef-59501f0d3f8b"></a><a name="section-12"></a><p></p>
<h1>Lithium Carbonate 450 mg ER</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9efc1d04-7aae-4ca9-9af6-ea6f3e095db2&amp;name=68151-0245.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LITHIUM CARBONATE 		
					</strong><br><span class="contentTableReg">lithium carbonate tablet, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68151-0245(NDC:0054-0020)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LITHIUM CARBONATE</strong> (LITHIUM CATION) </td>
<td class="formItem">LITHIUM CARBONATE</td>
<td class="formItem">450 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM ALGINATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (speckled, off-white to yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54;346</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68151-0245-2</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076691</td>
<td class="formItem">01/05/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Carilion Materials Management
							(079239644)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Carilion Materials Management (079239644)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carilion Materials Management</td>
<td class="formItem"></td>
<td class="formItem">079239644</td>
<td class="formItem">REPACK(68151-0245)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>972970a5-df24-457b-b22d-fe3c6a86bef1</div>
<div>Set id: 9efc1d04-7aae-4ca9-9af6-ea6f3e095db2</div>
<div>Version: 2</div>
<div>Effective Time: 20111208</div>
</div>
</div> <div class="DistributorName">Carilion Materials Management</div></p>
</body></html>
